Interesting results from the CAAN-AF trian presented by Prash Sanders at #ESC2025 - no benefit from AVN ablation in pts with CRTD and incomplete BiV pacing ... In contrast to observational studies and ESC guidelines!

3) CAAN-AF on CRT-D patients with permanent AF ➡️ AVN ablation vs drug therapy showing no difference 🚨 in HF mortality and HF events 🇦🇺 4) Analysis of PRAETORIAN and ATLAS populations on an ⬆️ of inappropriate shocks on S-ICD vs TV-ICD!! 🇨🇦🇳🇱

LBBAP in HFrEF and LBBB maybe is not dead yet, but seriously wounded. Curious to see results by subgroup based on effective/durable LBB capture.

📌Great late-breaking clinical trial session : First RCT to evaluate AV node ablation in CRT-D patients with HFrEF & permanent AF. Congrats to our leader Prash Sanders #ESC2025 #chrd

Worth reading like anything from John Mandrola, MD Several months ago one man speculated also about betablockers versus digoxin use in AF with HFrEF... Here also some good point in the discussion. Next trial, please, no digitoxin in Slovakia (at least one thing in common with the USA🤓).

After STROKE-STOP and STROKE-STOP II, AMALFI again questions any benefit of screening for A Fib. While more people are diagnosed with A Fib, and despite a trend for more anticoagulation, stroke rates are not reduced in AMALFI #ESCCongress2025 jamanetwork.com/journals/jama/…

#VICTOR #ESCCongress #LBCT 🫀Vericiguat in Chronic #HFrEF 🫀population:1/2 no prior HF hospitalization, excellent GDMT 🫀 Nonetheless, no significant finding of difference of Vericiguat 🆚 Placebo 🫀did ⤵️ risk of CV death

Presented at #ESCCongress: In patients with nonobstructive HCM, mavacamten did not significantly improve peak oxygen uptake or decrease symptoms as compared with placebo, and more patients had a reduction in LVEF with mavacamten. Full ODYSSEY-HCM phase 3 trial results:

Simultaneous publication during #ESCCongress 2-Year Outcomes of Left Bundle Branch Area Pacing Versus Traditional Right Ventricular Pacing in middle-aged Adults: A Registry-Based Trial ow.ly/3FsQ50WOvyh #Europace

Presented at #ESCCongress: Among patients with myocardial infarction and a left ventricular ejection fraction of at least 40%, beta-blockers led to a lower risk of death or major cardiovascular events than no beta-blocker therapy. Full BETAMI–DANBLOCK trial results:

REBOOT & BETAMI-DanBlock @ESCcongress Madrid: ▪️ REBOOT – No prognostic benefit of beta-blockers post-MI with preserved or mildly reduced LVEF; possible harm in women ▪️ BETAMI – Beta-blockers associated with better outcomes

Beta-Blockers after Myocardial Infarction in Patients without Heart Failure: NEJM @ESCCongress 🥸 Is evidence still in favor of beta blockers post AMI? #ESCCongress2025 😱Summary 👇👇👇

REFINE ICD trial Very important study, answering very critical question ⬇️⬇️⬇️ Prophylactic ICD didn’t reduce mortality or SCD post MI in patients with persistent LVEF 36-50% and abnormal autonomic tone/ cardiac reploarisation on holter #ESCCongress #EPeeps

Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) nej.md/3HQHLfj #ESCCongress | European Society of Cardiology

#LBCT #ESCCongress #CVPrev #Vaccines #HeartFailure Population Assessment of #Influenza & Disease Activities #PANDAII study 🐼 💉1/3 of HF deteriorations precipitated by infections but evidence specific to pts with HF limited 💉study from China: #flu vaccine not covered by

#ESCCongress 🇪🇸 AI to improve management of cardiac arrhythmias 👉”Patient is not only a left atrial size” - substrate, triggers, comorbidities, biomarkers and clinical environment are crucial components that must be integrated into AI models 👉 Dynamic and multimodal ML

VT session at #ESCCongress chaired by Andrea Sarkozy & Petr Peichl Gerhard Hindricks on non-sustained VT in device pts: 📉 Knowledge gaps, no RCTs 📊 No ↑ mortality evidence 🫀 Evaluate structural disease 😷 Treat based on symptoms 🤝 Define & share goals with patient

Outcomes in patients with cardiac amyloidosis undergoing catheter ablation for atrial arrhythmias, by Adrian Petzl and colleagues Penn Electrophysiology Fellowship Penn Medicine #EPeeps heartrhythmopen.com/article/S2666-…

Flecainide in Structural Heart Diseases: A Contemporary Reappraisal Beyond the CAST Trial heartrhythmjournal.com/article/S1547-…

Presented at #ESCCongress: In patients with chronic coronary syndrome taking oral anticoagulants, adding aspirin led to higher risks of cardiovascular events, major bleeding, and death from any cause than anticoagulation alone. Full AQUATIC trial: nej.md/45AU4Wp